发明名称 |
Combination pharmaceuticals and methods thereof using proteinacious channels as treatments for medical conditions |
摘要 |
Methods and combination pharmaceuticals for treating bronchospastic medical conditions by utilizing the electrophysiology of proteinacious channels in lipid membranes of mammalian cells. The combination pharmaceuticals include at least one β-adrenergic receptor agonist, and at least one composition adapted to effect the electrophysiology of Kv7 potassium channels of a lipid membrane of an airway smooth muscle cell. The pharmaceutical may be administered to a living body in a therapeutic amount sufficient to activate the Kv7 potassium channels of an airway smooth muscle cell. |
申请公布号 |
US9326955(B2) |
申请公布日期 |
2016.05.03 |
申请号 |
US201414174902 |
申请日期 |
2014.02.07 |
申请人 |
Loyola University Chicago |
发明人 |
Byron Kenneth L. |
分类号 |
A61K31/38;A61K31/155;A61K31/167;A61K31/27;A61K31/415;A61K31/555;G01N33/50;G01N33/68 |
主分类号 |
A61K31/38 |
代理机构 |
Hartman Global IP Law |
代理人 |
Hartman Global IP Law ;Hartman Gary M.;Hartman Domenica N. S. |
主权项 |
1. A combination pharmaceutical comprising:
at least one β-adrenergic receptor agonist, wherein sustained or repetitive exposure by a subject to the β-adrenergic receptor agonist induces receptor desensitization in the subject; and at least one composition that activates Kv7 potassium channels of a lipid membrane of an airway smooth muscle cell; wherein the combination of the β-adrenergic receptor agonist and the composition mitigates the effects of the receptor desensitization induced by the β-adrenergic receptor agonist. |
地址 |
Maywood IL US |